Pembrolizumab Regimen Approved in China for Frontline Squamous NSCLC

November 26, 2019 – China’s National Medical Products Administration (NMPA) has approved the combination of pembrolizumab plus carboplatin and paclitaxel for the first-line treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC). The approval is based on interim overall survival (OS) findings from the phase III KEYNOTE-407 trial, as well as interim data that were part of an extension of the international study in Chinese patients … (leggi tutto)